| Nicholas Slade Smith, MD | |
|
119 E Shore Rd, Monroe, LA 71203-8857 | |
| (318) 372-3815 | |
| Not Available |
| Full Name | Nicholas Slade Smith |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 17 Years |
| Location | 119 E Shore Rd, Monroe, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285834481 | NPI | - | NPPES |
| 1007200 | Medicaid | LA | |
| 06746150 | Other | LA | ECFMG |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD.203798 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rapid Urgent Care Inc | 0840437174 | 40 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Correct Care, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215987441 PECOS PAC ID: 8628980992 Enrollment ID: O20040816000150 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Emergency Staffing Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477590974 PECOS PAC ID: 9830001650 Enrollment ID: O20050610000177 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Ed Physicians Of West Louisiana, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255460143 PECOS PAC ID: 4880795665 Enrollment ID: O20070724000101 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Northern Louisiana Emergency Physicians, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588828172 PECOS PAC ID: 9638246846 Enrollment ID: O20080930000036 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Northern Louisiana Emergency Physicians, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598995847 PECOS PAC ID: 9638246846 Enrollment ID: O20090903000029 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Rapid Urgent Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285970780 PECOS PAC ID: 0840437174 Enrollment ID: O20130506000203 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Ess Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881967305 PECOS PAC ID: 6103085295 Enrollment ID: O20130515000072 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Entity Name | Concord North Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952761173 PECOS PAC ID: 2860791688 Enrollment ID: O20170922000452 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Slade Smith, MD 119 E Shore Rd, Monroe, LA 71203-8857 Ph: (318) 372-3815 | Nicholas Slade Smith, MD 119 E Shore Rd, Monroe, LA 71203-8857 Ph: (318) 372-3815 |
News Archive
ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
After a day of meetings with senior White House officials to discuss the U.S. preparations for H1N1 (swine) flu Tuesday, President Obama urged Americans to take the proper precautions to protect themselves from infection, the Associated Press/Boston Herald reports (9/1).
After a short period of growth, cultured networks of neurons regularly exhibit major activity in the absence of external stimulation. These "bursts" are entirely related to growth. At this stage, they have little to do with learning behaviour, as the network is still too young to sustain a process of memory formation. This has now for the first time been simulated for networks ranging in size from 10,000 to 50,000 neurons. The simulations provide insight into the role of the growth process in initial activity.
Today 23andMe, an industry leader in personal genetics, announced the discovery of two significant, novel genetic associations with Parkinson's disease (PD) and provided new evidence that there is a substantial genetic component remaining to be discovered for Parkinson's.
American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.
› Verified 1 days ago
Dr. Oladapo Lapite, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 306 Stone Ave, Monroe, LA 71201 Phone: 318-323-1040 Fax: 318-323-1134 | |
David L. Barnes, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 Medical Park Dr, Suite C, Monroe, LA 71203 Phone: 318-325-6078 Fax: 318-324-9694 | |
Dr. James Dean Stockstill, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3510 Magnolia Cv, Suite 190, Monroe, LA 71203 Phone: 318-323-7576 Fax: 318-322-7131 | |
Dr. Tobe Samuel Momah, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2913 Desiard St, Monroe, LA 71201 Phone: 318-651-9914 Fax: 318-388-0948 | |
Dr. Madelyn H Corkern, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 920 Oliver Rd # A, Monroe, LA 71201 Phone: 318-807-4951 Fax: 318-812-0808 | |
Mr. Michael T Hayward Sr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 Medical Park Dr, Suite B, Monroe, LA 71203 Phone: 318-387-6803 Fax: 318-387-6874 | |
Kermit L. Walters Jr., MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1910 Jackson St, Monroe, LA 71202 Phone: 318-325-7998 Fax: 318-398-0888 |